Dyadic International (DYAI) 1.0300 $DYAI
Dyadic International's (DYAI) CEO Mark Emalfarb Discusses on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 8:31PM CDT
Dyadic International Reports First Quarter 2015 Financial Results
GlobeNewswire - Thu May 14, 3:30PM CDT
-- Total Revenue up 35% Year-over-Year
Dyadic Receives Funding for New Advanced Biofuels Program
PR Newswire - Wed May 13, 3:15PM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding 2G BIOPIC, a new advanced biofuels project funded by the European Commission's Horizon 2020 program. In the 2G BIOPIC project, Dyadic's subsidiary Dyadic Netherlands B.V. ("Dyadic Netherlands" will work in collaboration with Compagnie Industrielle de Matiere Vegetale ("CIMV" and five other industry partners to develop, construct and operate a large demonstration-scale facility that produces ethanol from biomass.
Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015
PR Newswire - Mon May 04, 7:30AM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it will report its financial results for quarter ending March 31, 2015 after market close on Thursday, May 14, 2015 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.
Dyadic International Receives Two Additional Research Milestone Payments From BASF
PR Newswire - Tue Apr 28, 7:30AM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company with patented and proprietary technologies used to develop and produce enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today announced the receipt of $800,000 for achieving two additional research and development milestones in its funded research program with BASF, a Dyadic C1 Technology licensee.
Dyadic International Announces The Appointment Of Jack Kaye To Its Board of Directors
PR Newswire - Wed Mar 18, 3:15PM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI) today announced the appointment of Jack Kaye to the Board of Directors, effective April 1, 2015. Mr. Kaye will serve on the audit and compensation committees. With the addition of Mr. Kaye, there will be seven members on the Dyadic Board.
KERX: 10.33 (+0.11)
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 8:18PM CDT
Dyadic International Reports 2014 Year End Financial Results
PR Newswire - Wed Mar 11, 3:15PM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced today announced financial results for the year ended December 31, 2014.
Global Biocatalysis & Biocatalysts Market Report 2015-2019 with Novozymes, DuPont & DSM Featuring as the Most Active Players
M2 - Wed Mar 11, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxtvw4/biocatalysis_and) has announced the addition of the "Biocatalysis & Biocatalysts Market By Type (Hydrolases, Oxidoreductases, Transferases, And Others), Application (Food & Beverages, Cleaning Agents, Agriculture & Feed, Biofuel Production, Biopharmaceuticals, And Others), and Geography - Forecast to 2019 " report to their offering. The biocatalysts market was estimated around 81 kilo tons in 2013, with the high share of around 70% held by North America and Europe together. The global biocatalysts market by volume is projected to grow at a CAGR of 5.5% from 2014 to 2019. The high growth is forecasted to be in the RoW due to rise of end industries such as biofuel production, agriculture & feed, food and beverages in the region. Europe is estimated to have the second highest growth around 6.71% from 2014 to 2019. Advancements in the biocatalysis process have led to increased penetration of biocatalysts in different applications. Biofuel and detergent industries have the largest application of biocatalysts. Food & beverages, agriculture & feed, biopharmaceuticals are the other significant applications. Small applications include life science applications, textile, leather, pulp & paper, and flavor & fragrances. Biofuel and biopharmaceuticals applications are predicted to show the highest growth rate in the next five years. Hydrolases, transferases, and oxidoreductases are the major types of biocatalysts. The other three segments of biocatalysts lyases, isomerases, and ligases are small part of the biocatalysts market currently. The biocatalysts market is anticipated to show a high growth rate in the coming years. The market is innovation driven and investments are expected for new biocatalysis process and enzyme development. There are large numbers of various sized players in the market but it is dominated by few big companies. Currently, the biocatalyst market is mainly concentrated in the North American and European region while RoW region, especially Latin America is expected to show high growth rate in future years. Advancement in biocatalysis process along with increasing penetration of biocatalysts in different applications is driving the growth of the global biocatalysts market. Novozymes (Denmark), DuPont (U.S.), DSM (Netherlands) are the important active players in the biocatalysts market. These companies showed the highest strategy adoptions amongst other players in the biocatalysts market from 2010 to 2014. These companies together hold around 70% share of the biocatalysts market. From 2010 to 2014, partnership, agreement, and collaboration was observed as the most important growth strategy adopted by the major biocatalysts, accounting for a share of more than 50% of the total strategies adopted by the players. The other companies AB Enzymes (Germany), Codexis Inc. (U.S.), and BASF (Germany) also contributed to the market activities in the global biocatalysts market during the above mentioned period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Biocatalysis And Biocatalysts Market, By Type 8 Biocatalysis And Biocatalysts Market, By Application 9 Regional Analysis 10 Competitive Landscape 11 Company Profiles - Ab Enzymes Gmbh - Amano Enzymes - Basf Se - Chr. Hansen - Codexis Inc. - Dyadic International - E.I. Dupont De Nemours & Co. - Novozymes A/S - Royal Dsm N.V. - Soufflet Group For more information visit http://www.researchandmarkets.com/research/fx...alysis_and
CDXS: 4.50 (-0.13)
Dyadic International Raises $2 Million In Private Placement Of Convertible Note
PR Newswire - Mon Mar 09, 7:30AM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced that it has completed a private placement of $2,000,000 in convertible subordinated secured promissory note (the "Note" .
Dyadic Appoints Michael Tarnok As Chairman Of The Board Of Directors
PR Newswire - Mon Jan 12, 7:40AM CST
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok as the company's Chairman of the Board of Directors. Mr. Tarnok will continue to serve on the company's audit and compensation committees.
KERX: 10.33 (+0.11)
Dyadic International Extends Debt Maturity Date On Note Payable
PR Newswire - Mon Jan 05, 3:15PM CST
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has entered into an agreement to extend the maturity date of the $1.4 million non-convertible 9.5% note payable (the "Debt" to January 1, 2016. All other terms and conditions of the Debt remain unchanged.
Dyadic International Reports Q3 2014 Financial Results
PR Newswire - Thu Nov 13, 3:15PM CST
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the third quarter ended September 30, 2014.
New U.S. Patent Issued To Dyadic International
PR Newswire - Wed Nov 12, 8:34AM CST
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,871,493 "Transformation system in the field of filamentous fungal hosts" by the United States Patent and Trademark Office ("USPTO" .
Dyadic International To Present At Two Conferences In November 2014
PR Newswire - Mon Nov 03, 3:48PM CST
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that the Company will present at the following conferences in November:
Dyadic International Extends All Convertible Debt Maturity Dates
PR Newswire - Thu Oct 30, 4:42PM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has entered into agreements with the holders of all of its outstanding 2010 and 2011 8% convertible subordinated notes (the "Convertible Debt" to extend their maturity dates to January 1, 2016.
Dyadic International To Announce Third Quarter 2014 Financial Results And Host Conference Call On Thursday, November 13, 2014
PR Newswire - Thu Oct 30, 3:50PM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it will report its financial results for the third quarter ended September 30, 2014 after market close on Thursday, November 13, 2014 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results.
Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes
PR Newswire - Wed Oct 01, 7:30AM CDT
Dyadic International, Inc. ("Dyadic" (OTCQX: DYAI), a global biotechnology company with patented and proprietary technology used to develop and produce enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today announced the receipt of a $500,000 licensing payment from Abengoa Bioenergy for commercial scale production of Abengoa's proprietary cellulase enzymes, used for converting biomass into ethanol, developed under Abengoa's license agreement with Dyadic.
Analyzing the Market for Cellulosic Ethanol - 2014
M2 - Wed Sep 17, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38rww8/analyzing_the) has announced the addition of the "Analyzing the Market for Cellulosic Ethanol - 2014" report to their offering. This report is a complete handbook on this dynamic fuel source and its position in the global energy scenario. The report builds on the global energy industry and the consumption patterns which are fed by the traditional sources like Oil, Coal, Natural Gas, Nuclear Energy and Hydroelectricity. The report also presents a track on the global energy consumption patterns along with the resources being used for them. Taking into consideration the revenue cycles in the global energy markets, the report explains the revenue derived from these demand patterns from traditional sources as well as hydroelectric and wind energy. The report further also details each source individually. Taking a contrasting view point the report presents an in depth analysis of the global energy crisis and the growing recognition of unconventional energy sources for arresting this crisis. Key Topics Covered: A. Executive Summary B. Analyzing the Global Energy Industry C. Revenue Returns on Global Energy Markets D. Global Energy Demand & Supply Dynamics E. Looking at the Global Energy Crisis F. Emergence of Ethanol as an Energy Source G. Introduction to Cellulosic Ethanol H. Analyzing the Major Conversion Technologies: Producing Ethanol from Cellulosic Feedstocks I. Analyzing Ethanol Production from Different Feedstocks J. Analyzing the Utility of Ethanol in Transportation K. Commercializing Cellulosic Ethanol L. Factors Impact Growth of the Industry M. Challenges & Issues Facing the Industry N. Technological Patterns Prominent in the Industry O. Role of Industrial Biotechnology in the Development of Cellulosic Ethanol P. Production Patterns Q. Influence of Cellulosic Ethanol on the Farm Economy R. Ethanol Production and Use - Impact on the Economy S. Analyzing the Economics of Ethanol Production T. Analyzing the Regulatory Framework U. Government Incentives & Support Mechanisms V. Leading Industry Players - Abengoa Bioenergy Corporation - Archer Daniels Midland Co. - Aventine Renewable Energy Holdings - Cargill - Codexis, Inc - Dyadic International, Inc - Genencor International - Green Plains Renewable Energy. - Iogen Corporation - Lignol - Mascoma Corporation - NatureWorks, LLC - Novozymes - Pacific Ethanol, Inc. - Renova Energy (Wyoming Ethanol) - SunOpta - Tate & Lyle - The Andersons Inc. - U.S. BioEnergy Corporation - VeraSun Energy Corporation - Verenium - Xethanol BioFuels, LLC For more information visit http://www.researchandmarkets.com/research/38...lyzing_the
ADM: 53.04 (+0.16), GPRE: 31.67 (-0.20), CDXS: 4.50 (-0.13)
Dyadic International's (DYAI) CEO Mark Emalfarb Discusses on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 8:31PM CDT
Dyadic International Reports First Quarter 2015 Financial Results
GlobeNewswire - Thu May 14, 3:30PM CDT
-- Total Revenue up 35% Year-over-Year
Dyadic Receives Funding for New Advanced Biofuels Program
PR Newswire - Wed May 13, 3:15PM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding 2G BIOPIC, a new advanced biofuels project funded by the European Commission's Horizon 2020 program. In the 2G BIOPIC project, Dyadic's subsidiary Dyadic Netherlands B.V. ("Dyadic Netherlands" will work in collaboration with Compagnie Industrielle de Matiere Vegetale ("CIMV" and five other industry partners to develop, construct and operate a large demonstration-scale facility that produces ethanol from biomass. Dyadic International To Announce First Quarter 2015 Financial Results and Host Conference Call On Thursday, May 14, 2015
PR Newswire - Mon May 04, 7:30AM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it will report its financial results for quarter ending March 31, 2015 after market close on Thursday, May 14, 2015 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. Dyadic International Receives Two Additional Research Milestone Payments From BASF
PR Newswire - Tue Apr 28, 7:30AM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company with patented and proprietary technologies used to develop and produce enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today announced the receipt of $800,000 for achieving two additional research and development milestones in its funded research program with BASF, a Dyadic C1 Technology licensee. Dyadic International Announces The Appointment Of Jack Kaye To Its Board of Directors
PR Newswire - Wed Mar 18, 3:15PM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI) today announced the appointment of Jack Kaye to the Board of Directors, effective April 1, 2015. Mr. Kaye will serve on the audit and compensation committees. With the addition of Mr. Kaye, there will be seven members on the Dyadic Board. KERX: 10.33 (+0.11)
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Mar 11, 8:18PM CDT
Dyadic International Reports 2014 Year End Financial Results
PR Newswire - Wed Mar 11, 3:15PM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced today announced financial results for the year ended December 31, 2014. Global Biocatalysis & Biocatalysts Market Report 2015-2019 with Novozymes, DuPont & DSM Featuring as the Most Active Players
M2 - Wed Mar 11, 7:46AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fxtvw4/biocatalysis_and) has announced the addition of the "Biocatalysis & Biocatalysts Market By Type (Hydrolases, Oxidoreductases, Transferases, And Others), Application (Food & Beverages, Cleaning Agents, Agriculture & Feed, Biofuel Production, Biopharmaceuticals, And Others), and Geography - Forecast to 2019 " report to their offering. The biocatalysts market was estimated around 81 kilo tons in 2013, with the high share of around 70% held by North America and Europe together. The global biocatalysts market by volume is projected to grow at a CAGR of 5.5% from 2014 to 2019. The high growth is forecasted to be in the RoW due to rise of end industries such as biofuel production, agriculture & feed, food and beverages in the region. Europe is estimated to have the second highest growth around 6.71% from 2014 to 2019. Advancements in the biocatalysis process have led to increased penetration of biocatalysts in different applications. Biofuel and detergent industries have the largest application of biocatalysts. Food & beverages, agriculture & feed, biopharmaceuticals are the other significant applications. Small applications include life science applications, textile, leather, pulp & paper, and flavor & fragrances. Biofuel and biopharmaceuticals applications are predicted to show the highest growth rate in the next five years. Hydrolases, transferases, and oxidoreductases are the major types of biocatalysts. The other three segments of biocatalysts lyases, isomerases, and ligases are small part of the biocatalysts market currently. The biocatalysts market is anticipated to show a high growth rate in the coming years. The market is innovation driven and investments are expected for new biocatalysis process and enzyme development. There are large numbers of various sized players in the market but it is dominated by few big companies. Currently, the biocatalyst market is mainly concentrated in the North American and European region while RoW region, especially Latin America is expected to show high growth rate in future years. Advancement in biocatalysis process along with increasing penetration of biocatalysts in different applications is driving the growth of the global biocatalysts market. Novozymes (Denmark), DuPont (U.S.), DSM (Netherlands) are the important active players in the biocatalysts market. These companies showed the highest strategy adoptions amongst other players in the biocatalysts market from 2010 to 2014. These companies together hold around 70% share of the biocatalysts market. From 2010 to 2014, partnership, agreement, and collaboration was observed as the most important growth strategy adopted by the major biocatalysts, accounting for a share of more than 50% of the total strategies adopted by the players. The other companies AB Enzymes (Germany), Codexis Inc. (U.S.), and BASF (Germany) also contributed to the market activities in the global biocatalysts market during the above mentioned period. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Biocatalysis And Biocatalysts Market, By Type 8 Biocatalysis And Biocatalysts Market, By Application 9 Regional Analysis 10 Competitive Landscape 11 Company Profiles - Ab Enzymes Gmbh - Amano Enzymes - Basf Se - Chr. Hansen - Codexis Inc. - Dyadic International - E.I. Dupont De Nemours & Co. - Novozymes A/S - Royal Dsm N.V. - Soufflet Group For more information visit http://www.researchandmarkets.com/research/fx...alysis_and
CDXS: 4.50 (-0.13)
Dyadic International Raises $2 Million In Private Placement Of Convertible Note
PR Newswire - Mon Mar 09, 7:30AM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced that it has completed a private placement of $2,000,000 in convertible subordinated secured promissory note (the "Note" . Dyadic Appoints Michael Tarnok As Chairman Of The Board Of Directors
PR Newswire - Mon Jan 12, 7:40AM CST
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins, announced today the appointment of Michael Tarnok as the company's Chairman of the Board of Directors. Mr. Tarnok will continue to serve on the company's audit and compensation committees. KERX: 10.33 (+0.11)
Dyadic International Extends Debt Maturity Date On Note Payable
PR Newswire - Mon Jan 05, 3:15PM CST
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has entered into an agreement to extend the maturity date of the $1.4 million non-convertible 9.5% note payable (the "Debt" to January 1, 2016. All other terms and conditions of the Debt remain unchanged. Dyadic International Reports Q3 2014 Financial Results
PR Newswire - Thu Nov 13, 3:15PM CST
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, today announced financial results for the third quarter ended September 30, 2014. New U.S. Patent Issued To Dyadic International
PR Newswire - Wed Nov 12, 8:34AM CST
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has been issued U.S. Patent No. 8,871,493 "Transformation system in the field of filamentous fungal hosts" by the United States Patent and Trademark Office ("USPTO" . Dyadic International To Present At Two Conferences In November 2014
PR Newswire - Mon Nov 03, 3:48PM CST
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that the Company will present at the following conferences in November: Dyadic International Extends All Convertible Debt Maturity Dates
PR Newswire - Thu Oct 30, 4:42PM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it has entered into agreements with the holders of all of its outstanding 2010 and 2011 8% convertible subordinated notes (the "Convertible Debt" to extend their maturity dates to January 1, 2016. Dyadic International To Announce Third Quarter 2014 Financial Results And Host Conference Call On Thursday, November 13, 2014
PR Newswire - Thu Oct 30, 3:50PM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company whose patented and proprietary technologies are used to develop, manufacture and sell enzymes and other proteins for the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme industries, announced today that it will report its financial results for the third quarter ended September 30, 2014 after market close on Thursday, November 13, 2014 and will host a conference call that day at 5:00 p.m. Eastern Time to discuss those results. Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes
PR Newswire - Wed Oct 01, 7:30AM CDT
Dyadic International, Inc. ("Dyadic"
(OTCQX: DYAI), a global biotechnology company with patented and proprietary technology used to develop and produce enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, today announced the receipt of a $500,000 licensing payment from Abengoa Bioenergy for commercial scale production of Abengoa's proprietary cellulase enzymes, used for converting biomass into ethanol, developed under Abengoa's license agreement with Dyadic. Analyzing the Market for Cellulosic Ethanol - 2014
M2 - Wed Sep 17, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/38rww8/analyzing_the) has announced the addition of the "Analyzing the Market for Cellulosic Ethanol - 2014" report to their offering. This report is a complete handbook on this dynamic fuel source and its position in the global energy scenario. The report builds on the global energy industry and the consumption patterns which are fed by the traditional sources like Oil, Coal, Natural Gas, Nuclear Energy and Hydroelectricity. The report also presents a track on the global energy consumption patterns along with the resources being used for them. Taking into consideration the revenue cycles in the global energy markets, the report explains the revenue derived from these demand patterns from traditional sources as well as hydroelectric and wind energy. The report further also details each source individually. Taking a contrasting view point the report presents an in depth analysis of the global energy crisis and the growing recognition of unconventional energy sources for arresting this crisis. Key Topics Covered: A. Executive Summary B. Analyzing the Global Energy Industry C. Revenue Returns on Global Energy Markets D. Global Energy Demand & Supply Dynamics E. Looking at the Global Energy Crisis F. Emergence of Ethanol as an Energy Source G. Introduction to Cellulosic Ethanol H. Analyzing the Major Conversion Technologies: Producing Ethanol from Cellulosic Feedstocks I. Analyzing Ethanol Production from Different Feedstocks J. Analyzing the Utility of Ethanol in Transportation K. Commercializing Cellulosic Ethanol L. Factors Impact Growth of the Industry M. Challenges & Issues Facing the Industry N. Technological Patterns Prominent in the Industry O. Role of Industrial Biotechnology in the Development of Cellulosic Ethanol P. Production Patterns Q. Influence of Cellulosic Ethanol on the Farm Economy R. Ethanol Production and Use - Impact on the Economy S. Analyzing the Economics of Ethanol Production T. Analyzing the Regulatory Framework U. Government Incentives & Support Mechanisms V. Leading Industry Players - Abengoa Bioenergy Corporation - Archer Daniels Midland Co. - Aventine Renewable Energy Holdings - Cargill - Codexis, Inc - Dyadic International, Inc - Genencor International - Green Plains Renewable Energy. - Iogen Corporation - Lignol - Mascoma Corporation - NatureWorks, LLC - Novozymes - Pacific Ethanol, Inc. - Renova Energy (Wyoming Ethanol) - SunOpta - Tate & Lyle - The Andersons Inc. - U.S. BioEnergy Corporation - VeraSun Energy Corporation - Verenium - Xethanol BioFuels, LLC For more information visit http://www.researchandmarkets.com/research/38...lyzing_the
ADM: 53.04 (+0.16), GPRE: 31.67 (-0.20), CDXS: 4.50 (-0.13)
